Because they completed Phase I safety trial. Now they will do Phase II trial for efficiency. Japan doesn’t require Phase III with new laws for regenenative medicine. If I understand correctly.Why should be a possibility to commercialize in 2024? I mean they will do the First Trial this Year so How they Can Skip Phase II and Phase III?
